EGFR and non-small cell lung carcinoma: Although EGFR-tyrosine kinase inhibitors (TKI) are the most preferred treatment option for EGFR-mutated NSCLC, some research revealed comparatively poor efficacy of EGFR-TKI for EGFR-mutated LSCC [2,3].